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The dopamine (DA) transporter (DAT) is a plasma membrane glycoprotein expressed in 
dopaminergic (DA-) cells that takes back DA into presynaptic neurons after its release. DAT 
dysfunction has been involved in different neuro-psychiatric disorders including Parkinson’s disease 
(PD). On the other hand, numerous studies support that the glial cell line-derived neurotrophic factor 
(GDNF) has a protective effect on DA-cells. However, studies in rodents show that prolonged GDNF 
over-expression may cause a tyrosine hydroxylase (TH, the limiting enzyme in DA synthesis) 
decline. The evidence of TH down-regulation suggests that another player in DA handling, DAT, 
may also be regulated by prolonged GDNF over-expression, and the possibility that this effect is 
induced at GDNF expression levels lower than those inducing TH down-regulation. This issue was 
investigated here using intrastriatal injections of a tetracycline-inducible adeno-associated viral 
vector expressing human GDNF cDNA (AAV-tetON-GDNF) in rats, and doxycycline (DOX; 0.01, 
0.03, 0.5 and 3 mg/ml) in the drinking water during 5 weeks. We found that 3mg/ml DOX promotes 
an increase in striatal GDNF expression of 12x basal GDNF levels and both DA uptake decrease and 
TH down-regulation in its native and Ser40 phosphorylated forms. However, 0.5 mg/ml DOX 
promotes a GDNF expression increase of 3x basal GDNF levels with DA uptake decrease but not TH 
down-regulation. The use of western-blot under non-reducing conditions, co-immunoprecipitation 
and in situ proximity ligation assay revealed that the DA uptake decrease is associated with formation 
of DAT dimers and an increase in DAT-α-synuclein interactions, without changes in total DAT 
levels or its compartmental distribution. In conclusion, at appropriate GDNF transduction levels, DA 
uptake is regulated through DAT protein-protein interactions without interfering with DA synthesis. 
Key words: dopamine transporter, tyrosine hydroxylase, GDNF, inducible adeno-associated viral 
vectors, Parkinson's disease. 
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Introduction 
The uptake of dopamine (DA) into presynaptic terminals is the primary mechanism controlling 
the duration and intensity of DA signaling in post- and presynaptic DA receptors (Giros et al., 1996). 
The DA transporter (DAT) is a plasma membrane glycoprotein expressed in dopaminergic (DA-) 




-coupled cotransport mechanism (Giros and Caron,
1993; Freed et al., 1995). DAT dysfunction has been involved in a number of neuro-psychiatric 
disorders, including Parkinson’s disease (PD) (Le Couteur et al., 1997; Bezard et al., 1999; Storch et 
al., 2004). Taking into account that oxidative stress plays a central role in the pathogenesis of PD, 
that DA metabolism is the main source of reactive oxygen species in DA-cells, and that the cytosolic 
content in DA depends mostly on the DA uptake (Bannon, 2005), DAT activity has been involved in 
DA-cell degeneration in PD. This idea is supported on the fact that midbrain DA-cells showing high 
susceptibility to degeneration contain higher levels of DAT mRNA and glycosylated (functional) 
DAT protein than those showing resistance (Uhl et al., 1994; Afonso-Oramas et al., 2009). Moreover, 
DAT transports natural and synthetic DA analogue neurotoxins, and its blockade or deficient 
expression makes DA-cells resistant to these neurotoxins (Bezard et al., 1999; Schober, 2004; 
Afonso-Oramas et al., 2010).  
DAT is acutely regulated by different factors including extracellular DA levels, DA 
autoreceptors, and interactions with presynaptic proteins such as α-synuclein, protein kinases and 
phosphatases which promote either its trafficking to the plasma membrane and activity or its 
internalization (Mortensen and Amara, 2003; Wersinger and Sidhu, 2003; Miranda and Sorkin, 2007; 
Eriksen et al., 2010; Foster et al., 2012). On the other hand, phenotypic and functional properties of 
DA-cells, including DA transport, are maintained by different neurotrophic factors (Alexi et al., 
2000; Pascual et al., 2008; Apawu et al., 2013). Particular interest has been focused on the glial cell 
line-derived neurotrophic factor (GDNF). In vitro and in vivo experiments show that besides 
protecting DA-cells against different neurotoxins (Kirik et al., 2004; Garbayo et al., 2011), GDNF 
promotes tyrosine hydroxylase (TH, the limiting enzyme in DA synthesis) expression and DA 
release, turnover and uptake (Lin et al., 1993; Salvatore et al., 2004; Yang et al., 2009). Based on 
these findings, GDNF was proposed as a hopeful neuroprotective therapy in PD. However, further 
studies in rodents revealed that prolonged GDNF release may lead to TH down-regulation 
(Rosenblad et al., 2003; Georgievska et al., 2004), probably as a consequence of the elevated DA 
turnover induced by excessive GDNF over-expression (Rosenblad et al., 2003; Sajadi et al., 2005). 
So, it is possible that other players in DA handling are affected by sustained GDNF treatment. Given 
the role of DAT in DA handling and in the pathogenesis of PD, here we investigated whether DAT is 
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also regulated by prolonged GDNF treatment, and more important, if DAT may be regulated without 
affecting TH expression. Taking advantage of the fact that regulatable viral vectors allow a fine 
control of target gene expression through external inducers (Goverdhana et al., 2005; Chtarto et al., 
2013), experiments here were based on intrastriatal injections of a tetracycline-inducible adeno-
associated viral vector expressing human GDNF cDNA and treatment with different doses of 
doxycycline in rats.   
Material and methods 
Plasmids 
The pAC1-M2 plasmid comprising AAV ITRs bracketing the bidirectional tetracycline-responsive 
cassette expressing both rtTAM2 and EGFP has been previously described (Chtarto et al., 2007). To 
obtain pAC1-V16, the rtTA transactivator of pAC1 (Chtarto et al., 2003) was replaced by rtTAV16, a 
rtTA mutant selected in the presence of a low doxycycline dose (Zhou et al., 2006). The human 
GDNF cDNA (hGDNF) was introduced in this autoregulatory tetracycline inducible vector at the 5’ 
end of the bi-directional tetracycline promoter (ptetbidiON). 
Viral production 
To produce recombinant AAV2/1 viral stocks, HEK-293T cells (5.0 x 10
6
 cells per 10 cm plates)
were cotransfected, in a 1:1 molar ratio, with the vector plasmid (3 μg/ plate) together with the 
helper/packaging plasmid pD1rs (10 μg/ plate) expressing the AAV viral genes (rep gene from AAV 
serotype 2 and cap gene from AAV serotype 1) and the adenoviral genes required for AAV 
replication and encapsidation (Plasmid Factory, Heidelberg, Germany). Fifty hours post-transfection, 
the medium was discarded and the cells were harvested by low-speed centrifugation and resuspended 
in Tris pH 8.0, NaCl 0.1 M. After three cycles of freezing/thawing, the lysate was clarified by 30 min 
centrifugation at 10 000 g, treated with benzonase (50 units/ml, Sigma, St Louis, MO) at 37°C for 
30 min, and centrifuged at 10 000 g for 30 min to eliminate the residual debris. The virus was further 
purified by iodixanol gradient according to a well-established method (Zolotukhin et al., 2002). Viral 
genomes (vg) were titrated by quantitative PCR as previously described (Lock et al., 2010).   
Animals 
The experiments were carried out on male Sprague–Dawley rats (300-350 g; Charles River, 
France). Rats were housed in groups of 3–4 per cage, in conditions of constant temperature (21–22 
°C), a 12 h light/ dark cycle, and given free access to food and water. Experimental protocols were 




accordance with the European Communities Council Directive of 22 September 2010 (2010/63/EU) 
regarding the care and use of animals for scientific purposes. 
Stereotaxic injections (David Kopf Instruments, Tujunga, CA) were performed under ketamine 
(Imalgene®, 100 mg/kg i.p.) and xylazine (Rompun®; 45 mg/kg, i.p.) anesthesia using a syringe 
(Hamilton 701N, Reno, N V) with a 26S gauge blunt-tip needle. Rats received 3 µl of a viral 
suspension of recombinant AAV2/1-V16-hGDNF (n =18) or AAV2/1-V16-EGFP (n=14), or vehicle 
(dulbecco's phosphate-buffered saline; BioWhittaker, Walkersville, MD, USA; n = 14) in the left 
striatum. Viral suspension (3.5x 10
11 
vg/ml) and vehicle were delivered in two deposits (1.5 µl each) 
0.7 mm apart along the same needle tract at a diffusion rate of 0.5 μl/min at the following 
coordinates: 0.5 mm rostral to bregma, 2.6 mm lateral to midline, and 5.2 mm (first deposit) and 4.5 
mm (second deposit) ventral from the skull surface (Paxinos and Watson, 1998). After injection, the 
needle was left in place for 5 min to allow diffusion of the viral suspension in the parenchyma and 
then slowly removed. Viral vector injected rats were treated with doxycycline (DOX) in the drinking 
water containing 3% sucrose at a concentration of 0.01, 0.03, 0.5 and 3 mg/ml since the injection day 
to the sacrifice. Animals were sacrificed by an overdose of sodium pentobarbital at 5 weeks after 
injection and the brains were removed and processed for morphological and biochemical analysis. A 
group of rats receiving 3 mg /ml DOX was maintained without DOX treatment for 20 additional days 
before sacrifice.  Experimental groups included at least 5 rats in each experiment. 
  
DAT antibodies 
 Several commercial anti-DAT antibodies against different fragments of human and rat DAT 
have been tested in our laboratory to determine their specificity and sensitivity. Brain samples of 
different mammalians and cells transfected with wild type and mutated DAT forms were processed 
for immunohistochemistry, western-blot and immunoprecipitation (see Alfonso-Oramas et al., 2009, 
2010; Cruz-Muros et al., 2009).  Taking into account the results of these tests, a goat anti-DAT 
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used for western-blot, and a 
rabbit anti-DAT polyclonal antibody (Millipore, Billerica, MA) for immunoprecipitation. For the 
study of DAT-DAT interaction using in situ proximity ligation assays, the goat anti-DAT polyclonal 
antibody was combined with a rabbit anti-DAT polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA). 
GDNF immunohistochemistry 
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Animals were transcardially perfused with heparinized ice-cold 0.9% saline followed by 4% 
paraformaldehyde in PBS, pH 7.4. The brains were removed, and the midbrain and forebrain blocks 
were stored in the same fixative at 4 °C overnight, cryoprotected in a graded series of sucrose–PBS 
solutions, and stored at −80 °C until processing. Coronal sections (30 µm) were obtained with a 
freezing microtome and collected in 6-8 parallel series. Floating sections were immersed for 30 
minutes in 3% H2O2 to inactivate endogenous peroxidase, and incubated for 60 minutes at RT in 4% 
normal donkey serum (NDS, Jackson ImmunoResearch, West Grove, PA) in PBS, containing 0.05% 
Triton X-100 (TX-100, Sigma), and overnight in PBS containing 2% NDS and a goat anti-GDNF 
polyclonal antibody (1:500; R&D Systems, Minneapolis, MN). After several rinses, sections were 
incubated for 2 h in biotinylated donkey anti-goat antiserum (1:1000, Jackson ImmunoResearch) and 
1:200 NDS in PBS. Immunoreactions were visible after incubation for 1 h at RT in ExtrAvidin-
peroxidase (1:5000, Sigma) in PBS, and after 10 minutes in 0.005% 3´-3´-diamiobenzidine 
tetrahydrochloride (DAB, Sigma) and 0.001% H2O2 in cacodylate buffer 0.05N pH 7.6.  
In situ proximity ligation assay (PLA) 
This technique is based on the use of oligonucleotide-conjugated antibodies, ligation of 
oligonucleotides by a bridging probe in a proximity-dependent manner, rolling-circle amplification, 
and visualization by complementary fluorescent probes (Söderberg et al., 2006). DAT-DAT 
interaction and DAT interactions with D2R and α-synuclein were studied using the Duolink II in situ 
PLA detection kit (Sigma) as described by Castro-Hernandez et al. (2015). Briefly, for the study of 
DAT-D2R and DAT-α-synuclein interactions, sections were incubated overnight at 4ºC with a goat 
polyclonal anti-DAT antibody (1:200; Santa Cruz Biotechnology) and one of the following 
antibodies in the antibody diluent: rabbit polyclonal anti-D2R antibody (1:200; Millipore) or rabbit 
polyclonal anti-α-synuclein antibody (1:200, Santa Cruz Biotechnology). Thereafter, sections were 
incubated (2 h, 37 °C) with PLA probes detecting goat and rabbit antibodies (Duolink II plus PLA 
probe anti-goat and Duolink II minus PLA probe anti-rabbit) and processed for ligation, 
amplification, and detection as described by the manufacturer. For the study of DAT-DAT 
interactions, sections were incubated with two anti-DAT antibodies directed to the C-terminus (1:200 
rabbit polyclonal anti-DAT and 1:200 goat-polyclonal anti-DAT) and PLA probes detecting rabbit 
(plus) and goat (minus) antibodies. For negative controls, one of the primary antibodies was 
substituted by non-immune goat or rabbit IgG, resulting in negative staining. Some sections were 
additionally processed for tyrosine hydroxylase (TH, the rate-limiting enzyme in DA synthesis) 




autofluorescence caused by the presence of fluorescent pigments such as lipofucsin or  elastin and 
also by the fixative, sections were treated with CuSO4 in ammonium acetate buffer (5 mM CuSO4, 
50 mM ammonium acetate pH  5.0) for 10 s (Zieba et al., 2010). After several washes they were 
mounted in mounting medium with DAPI and examined under a confocal laser scanning microscopy 
system (Olympus FV1000, Hamburg, Germany). Images were acquired in Z-stack mode (8.5 µm 
total thickness, 4 z-steps). Fluorescent PLA point-like signals were quantified, in number and size, in 
at least 12 striatal regions (400µm x 400µm) from 5 different rats per experimental group for each 
pair of primary antibodies, by using the ImageJ standard program. 
Striatal GDNF determination by enzyme-linked immunosorbent assay (ELISA) 
Five weeks after injection, rats (n=5 in each experimental group) were sacrificed and left striata 
were dissected in ice from freshly obtained brains using a brain blocker. The samples were sonicated 
in homogenization buffer (137mM NaCl, 20mM Tris (pH 8.0), 1% NP40, 10% glicerol, 1mM PMSF, 
10μg/ml aprotinin, 1μg/ml leupeptin and 0.5mM sodium vanadat) and striatal GDNF levels were 
determined by ELISA test following the manufacturer’s guidelines (commercial kit G7620, Promega 




H]-DA uptake  
Rat striata were obtained as described for GDNF ELISA, and processed according to Afonso-
Oramas et al. (2009). Samples were immediately homogenized in 20 vol of ice-cold sucrose 
bicarbonate solution (SBS, 320 mM sucrose in 5 mM sodium bicarbonate, pH 7.4) with 12 up and 
down strokes in a Teflon-glass homogenizer. The homogenates were centrifuged (1000 x g, 10 min, 
4ºC), and the pellets (P1) containing nuclei and large debris discarded. The supernatants (S1) were 
centrifuged (17,000 x g, 20 min, 4ºC), and the pellets (P2) were resuspended in 500 µl ice-cold assay 
buffer (125 mM NaCl, 5 mM KCl, 1.5 mM MgSO4, 1.25 mM CaCl2, 1.5 mM KH2PO2, 10 mM 
glucose, 25 mM HEPES, 0.1 mM EDTA, 0.1 mM pargyline and 0.1mM ascorbic acid). For [
3
H]-DA 
uptake assays, a range of temperatures (25-35ºC), DA concentrations (20-500 nM), incubation times 
(5-30 min) and striatal protein concentrations (0.2-3μg/μl) were checked in order to establish the 
working parameters in the linear ascending segment of the uptake curve.  Fifty µl of synaptosomal 
suspension (0.5 μg total protein/μl) were preincubated with 50 nM DA (Sigma) with or without 10 
μM nomifensine (Sigma) in assay buffer (30 ºC, 5 min). Subsequently, 20 nM [3H]-DA (final 
concentration; Amersham, Buckinghamshire, UK) was added to each tube. The total assay volume 
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was 200 μl. After 10 min incubation at 30 ºC, DA uptake was stopped by the addition of 200 μl ice-
cold assay buffer. The suspension was immediately filtered under vacuum through MultiScreen®- 
0.45 μm hydrophilic filters (Millipore, Molsheim, France). The filters were washed twice with 200 μl 
ice-cold assay buffer, excised and placed in scintillation vials containing 3 ml liquid scintillation 
Cocktail (Sigma), and stored overnight at room temperature (RT). Accumulated radioactivity was 
quantified using a liquid scintillation counter (LKB Rackbeta 1214; Turku, Finland). Non-specific 
uptake, defined as the DA uptake in the presence of nomifensine, was subtracted from total uptake to 
define DAT-mediated specific uptake. All assays were performed in triplicate. 
Western-blot in whole striatal extracts and plasma membranes 
DAT expression was studied using western-blot analysis of total extracts and the plasma 
membrane fraction of striatal synaptosomes. The striata were dissected as described for DA uptake. 
Whole protein extracts were obtained using the acid phenol method, resuspended in 
radioimmunoprecipitation assay (RIPA) lysis buffer pH 7.4 containing protease and phosphatase 
inhibitor cocktails (Roche Diagnostics, Indianapolis, IN), and quantified using the bicinchoninic acid 
method and bovine serum albumin as standard. Plasma membranes were obtained following the 
impermeant biotynilation procedure (Salvatore et al., 2003). Synaptosomes (300 μg total protein) 
were incubated for 1 h at 4ºC with continual shaking in 500 μl of 1.5 mg/ml sulfo-NHS-biotin 
(Pierce, Rockford, IL) in PBS/Ca/Mg buffer (138 mM Na Cl, 2.7 mM kCl, 1.5 mM KH2PO2, 9.6 mM 
Na2HPO4, 1mM MgCl2, 0.1 mM CaCl2, pH 7.3) and centrifuged (8,000 x g, 4 min, 4ºC). In order to 
remove biotinylating reagents, the resulting pellets were resuspended in 1 ml ice-cold 100 mM 
glycine in PBS/Ca/Mg buffer and centrifuged (8,000 x g, 4 min, 4ºC). The resuspension and 
centrifugation steps were repeated. Final pellets were resuspended again in 1ml ice-cold 100 mM 
glycine in PBS/Ca/Mg buffer and incubated for 30 min at 4ºC. Samples were washed three more 
times in PBS/Ca/Mg buffer, and then lysed by sonication for 2-4 seconds in 300 μl Triton X-100 
buffer (10mM Tris, pH 7.4, 150 mM NaCl, 1mM EDTA, 1 %Triton X-100) containing protease and 
phosphatase inhibitor cocktails (Roche Diagnostics). After incubation in continuous shaking (30 min, 
4ºC), the lysates were centrifuged (18,000 x g, 30 min, 4ºC), and the supernatants were incubated 
with monomeric avidin bead - Triton X-100 buffer (100 μl) for 1 h at RT, and centrifuged (18,000 x 
g, 4 min, 4ºC). The resulting pellets (containing avidin-absorbed biotynilated surface proteins) were 
resuspended in 1 ml Triton X-100 buffer and centrifuged (18,000 x g, 4 min, 4ºC). Resuspension and 
centrifugation were repeated two more times, and the final pellets were stored.  
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Protein samples for western-blot analysis were diluted in Laemmli’s loading buffer (62.5 mM 
Tris-HCl, 20% glycerol, 2% sodium dodecyl sulfate [SDS; Sigma], 1.7% β-mercaptoethanol and 
0.05% bromophenol blue, pH 6.8), denatured (90ºC, 1 min.), separated by electrophoresis in 10 % 
SDS-polyacrylamide gel, and transferred to nitrocellulose (Schleicher & Schuell, Dassel, Germany). 
Blots were blocked for 2 hs at RT with 5% non-fat dry milk in TBST (250 mM NaCl, 50mM Tris, pH 
7.4, and 0.05% Tween20), and incubated overnight at 4ºC in blocking solution with one of the 
following primary antibodies: a goat polyclonal anti-DAT antibody (1:500, Santa Cruz 
Biotechnology), a mouse monoclonal antibody that recognized native tyrosine hydroxylase  (TH; 
Sigma; 1:10,000, overnight, 4 °C), a rabbit polyclonal antibody recognizing rat TH amino acids 
residues surrounding the phospho-serine 40 (THp40; PhosphoSolutions, Aurora, CO; 1:1000, 
overnight, 4°C) and a mouse anti-β-Actin antibody (Sigma,1:10,000, 2 h, RT). After several rinses in 
TBST-5% milk, the membranes were incubated for 1 h in horseradish peroxidase conjugated anti-
goat (1:5000), anti-rabbit (1:10,000) or anti-mouse (1:20,000) IgG (Jackson-ImmunoResearch). In 
Western blot for the THp40, milk was substituted by 5% bovine serum albumin in the blocking 
solution. Immunoreactive bands were visualized using enhanced chemiluminiscence (Immun-Star, 
Bio-Rad, CA) and a Chemi-Doc
TM
 XRS imaging system (Bio-Rad, Hercules, CA).
Different protein quantities, antibody dilutions and exposure times were tested to establish the 
working range of each antibody. The labelling densities for DAT, TH and THp40 were compared 
with β-Actin by using densitometry software (Bio-Rad). A rectangle of uniform size and shape was 
placed over each band, and the density values were calculated by subtracting the background at 
approximately 2 mm above each band. The effectiveness of the plasma membrane fractionation was 
evaluated by using Syntaxin (mouse monoclonal anti-syntaxin, 1:500, Sigma) as a marker of 
synaptosomal membrane. 
Western-blot analysis under non-reducing conditions 
Western-blot analysis under non-reducing conditions was performed according to Baucum et 
al. (2004). Briefly, synaptosomes were obtained as described for DA uptake using 0.32 M sucrose, 
supplemented with protease inhibitor cocktail and PhosStop phosphatase inhibitor cocktail (Roche 
Diagnostics) and 10 mM N-ethylmaleimide (NEM; Sigma) as homogenization solution. P2 pellets 
were resuspended in mili-Q water, protein concentration was quantified, and samples were mixed 
with loading buffer (2.25% SDS, 18% glycerol, 180 mM Tris base, pH 6.8, and bromophenol blue). 




polyacrylamide gel containing 0.1% SDS, and transferred to nitrocellulose (Schleicher & Schuell). 
DAT immunostaining and quantification were performed as described above. 
Co-immunoprecipitation 
Co-immunoprecipitation was performed according to HadlocK et al. (2011) with minor 
modifications. Striatal tissue was homogenized in 1.5 ml ice-cold 10 mM HEPES, 0.32 M sucrose 
and 10 mM NEM pH 7.4, and centrifuged (800 x g, 12 min, 4ºC). The supernatants (S1) were 
centrifuged at 22,000 x g, 15 min, 4ºC, and the resulting pellets (P2) resuspended in 100 μl M-PER 
(Thermo Scientific, Rockford, IL). After 1 h at 4ºC in gentle shaking, samples were centrifuged 
again, the pellets were discarded, and protein concentration was quantified in supernatants. Aliquots 
of 500 μg proteins were incubated in protein A-Sepharose beads (100 μl stock suspension in 200 μl 
M-PER; 4ºC, 45 min) to pre-clear endogenous immunoglobulins. After gentle centrifugation, pre-
cleared supernatants were incubated with anti-DAT, anti-D2R or non-immune igG overnight at 4ºC 
in continuous shaking. In the experience of this laboratory, the most robust immunoprecipitates are 
obtained using 6 μl of rabbit polyclonal anti-DAT from Millipore®, rabbit polyclonal anti-D2R from 
Millipore®. Protein A-Sepharose beads (100 μl stock suspension in 200 μl M-PER) were added and 
maintained in continuous shaking at 4ºC for 3 h. Immuno-complexes were precipitated by gentle 
centrifugation. After extensive washing, they were resuspended in 40 μl Laemmli's buffer, denatured, 
separated by electrophoresis in 10 % SDS-polyacrylamide gel and transferred to nitrocellulose. Blots 
from DAT precipitates were immunoreacted for α-synuclein and DAT using a mouse monoclonal 
anti- α-synuclein (1: 500, BD Biosciences, San Jose, CA) and a goat polyclonal anti-DAT antibody 
(1:500, Santa Cruz Biotechnology). Blots from D2R precipitates were immunoreacted for DAT and 
D2R using a goat anti-DAT polyclonal (1:500, Santa Cruz Biotechnology) and a mouse monoclonal 
anti-D2R antibody (1:500, Santa Cruz Biotechnology). 
Statistics 
Mathematical analysis was performed using the one way ANOVA followed by the Tukey 
honest test for multiple post hoc comparisons. Analysis was performed using the Statistica program 
(Statsoft; Tulsa, U.S.A.). The degree of freedom in all comparisons was 1 (intergroup) and 8 
(intragroup). A level of p < 0.01 was considered as critical for assigning statistical significance. Data 









Regulated GDNF over-expression promotes DA uptake decrease without changes in DAT and TH 
expression. 
To determine the effect of different GDNF transduction levels on DAT and TH, viral vector 
injected rats were treated with doxycycline (DOX) for 5 weeks. DOX was administered in the 
drinking water at a concentration of 0.01, 0.03, 0.5 and 3 mg/ml. The daily drinking volume 
stabilized two days after GDNF injection at 57 ± 3 ml. As shown in Fig. 1A, striatal levels of GDNF 
in AAV-tetON-GDNF injected rats receiving 0.01 and 0.03 mg/ml DOX were similar to those in 
AAV-tetON-GFP injected rats receiving 0.01 and 3 mg/ml DOX, and sham injected untreated rats. In 
AAV-tetON-GDNF injected rats receiving 0.5 mg/ml DOX, GDNF transduction tripled the basal 
levels (69.3±3.6 vs. 22.6±5.2 pg/mg protein, p< 0.01; F= 12.18), and sparse neurons became 
immunoreactive for GDNF in the injection place (Figs. 1F, G). In rats receiving 3 mg/ml DOX, 
GDNF levels were 12 times higher (253.3±7.9 pg/mg protein; p< 0.001; F= 9.26) than in AAV-
tetON-GFP-injected rats, and many neurons became intensely immunoreactive for GDNF around the 
injection place (Figs. 1 H, I).  
Western-blot analysis of TH expression (Fig. 2A) revealed that, consistent with previous 
reports (Rosenblad et al., 2003; Georgievska et al., 2004), the levels of TH, in its native form, are 
decreased in striata with 12x basal GDNF over-expression (3 mg/ml DOX; 53%; p< 0.01, F= 6.31). 
However, no changes were detected in those with 3x basal GDNF over-expression (0.5 mg/ml DOX). 
TH phosphorylated at the Ser40 residue (THp40) followed the same pattern as the native form, with a 
decrease at 12x GDNF over-expression (80%; p< 0.01; F=12.48) but no changes at 3x GDNF 
overexpression. By contrast, the analysis of DAT expression in whole striatal extracts and in the 
plasma membrane of striatal terminals (Fig. 2B) revealed no differences between both experimental 
conditions,12x and 3x GDNF over-expression, and sham-injected rats. However, the analysis of 
nomifensine-sensitive DA uptake in striatal synaptosomes (Fig. 2C) revealed a significant DA uptake 
decrease in both 0.5 mg/ml DOX- (44.8  4.1 %, p< 0.01; F= 12.73) and 3 mg/ml DOX-treated rats 
(49.6  3.3 %; p< 0.01; F= 12.75) with respect to sham-injected rats. In addition, after 20 days 
without DOX, DA uptake returned to normal levels. These data indicate that sustained GDNF over-
expression induces a DA uptake decrease without changes in the expression levels and subcellular 
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distribution of DAT, and more interestingly, that a 3x increase in GDNF delivery reduces DA uptake 
without affecting TH expression.  
Prolonged GDNF over-expression induces the formation of DAT dimers and DAT- α-synuclein 
interactions 
The finding of a decrease in DA uptake but not in DAT levels in whole striatal extracts or 
synaptosomal membranes suggests that the effect of prolonged GDNF over-expression on DA uptake 
is not mediated by DAT expression down-regulation or internalization. Although trafficking between 
the plasma membrane and intracellular compartments and lysosomal degradataion are considered the 
standard mechanisms of DAT regulation (Mortensen and Amara, 2003; Eriksen et al., 2010b; Gabriel 
et al., 2013), we know that transporters may form complexes with themselves (Hastrup et al., 2001; 
Torres et al., 2003; Baucum et al., 2004) and other presynaptic proteins which regulate transporter 
activity (González and Robinson, 2004; Chen and Reith, 2008; Eriksen et al., 2010b). Thus, possible 
changes in DAT-DAT and DAT interactions with two well-known members of its proteome, α-
synuclein (Lee et al., 2001; Wersinger and Sidhu, 2005; Oaks and Sidhu, 2013) and D2 DA receptor 
(D2R; Lee et al., 2007) were thereafter investigated. 
As shown in Fig. 3A, the analysis of whole striatal extracts of sham-injected rats under non-
reducing conditions shows a dense band at ~75kDa, corresponding to the DAT glycosylated 
monomeric isoform (Afonso-Oramas et al., 2009), and a weak band at ~ 150 kDa, i.e. a molecular 
weight corresponding to DAT dimer. The immunoblot pattern in AAV-tetON-GFP-injected rats 
receiving 0.5 and 3 mg/ml DOX and AAV-tetON-GDNF-injected rats receiving 0.03 mg/ml DOX 
was similar to that of sham-injected rats (Fig, 3 A, lines 1, 2 and 3). However, the intensity of the 75 
kDa band became weaker in AAV-tetON-GDNF injected rats receiving 0.5 and 3 mg/ml DOX (a 
decrease of 63.5  8.4% in 0,5 mg/ml DOX with respect to Sham, p< 0.01, F =10.15; 74.1  6.7% in 
3 mg/ml DOX with respect to Sham, p< 0.01, F =11.29), and that at ~150 kDa became more intense 
(an increase of 123.5  8.1% in 0,5 mg/ml DOX with respect to Sham, p< 0.01, F = 11.46; 144.9  
6.8% in 3 mg/ml DOX with respect to Sham, p< 0.01, F = 13.80), suggesting that prolonged GDNF 
over-expression enhances the formation of DAT dimers. To confirm this idea, striatal sections of 
sham-, and AAV-tetON-GFP- and AAV-tetON-GDNF-injected rats treated with 0.5 mg/ml DOX, 
were processed for DAT-DAT in situ PLA using two anti-DAT antibodies against the same DAT 
epitope domain.  Consistent with the suggestion that the ~150 kDa band detected under non-reducing 
conditions corresponds to DAT dimers, sparse DAT-DAT PLA dots were present around striatal cells 
in sham and AAV-tetON-GFP-injected rats (Fig. 3B, left), and immunofluoescence for TH confirmed 
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their localization in DA-terminals (Fig. 3B, center and right). The quantitative analysis revealed no 
differences in the number and size of PLA signals between sham- and AAV-tetON-GFP-injected 
rats. However, significant differences were found between these two experimental groups and AAV-
tetON-GDNF-injected rats (Fig. 3C and D). The number of PLA dots in AAV-tetON-GDNF- 
injected rats was 81% and 77% higher than in sham (p < 0.01 vs. sham, F = 20.64) and AAV-tetON-
GFP-injected rats (p < 0.01 vs. AAV-tetON-GFP, F = 20.42, Fig. 3C) respectively. Likewise, the 
average dot size in AAV-tetON-GDNF-injected rats (96±7.6 pixels) tripled that of sham- (32±2.3 
pixels; p < 0.001; F = 26.78) and AAV-tetON-GFP-injected rats (34±6.2 pixels; p < 0.001; F = 19.92; 
Fig. 3D), with the largest dots probably corresponding to two or more PLA signals localized close to 
each other. These data together with the differences in the immunoblot pattern between AAV-tetON-
GFP- and AAV-tetON-GDNF-injected rats support the idea that prolonged GDNF over-expression 
induces DAT dimer formation. 
With respect to DAT- α-synuclein and DAT-D2R interactions, co-immunoprecipitation and in 
situ PLA corroborated previous reports (Lee et al., 2001; Wersinger and Sidhu, 2003; Lee et al., 
2007) showing that DAT constitutively maintains a physical interaction with both of them (Fig. 4A-
C). However, the response of these interactions to prolonged GDNF over-expression was different. In 
the case of DAT- α-synuclein, the amount of α-synuclein immunoprecipitated with DAT as well as 
the number and size of DAT- α-synuclein PLA dots in AAV-tetON-GDNF- injected rats were higher 
than in AAV-tetON-GFP-injected rats (Fig. 4A, B), suggesting that GDNF over-expression promotes 
DAT- α-synuclein interaction. In the case of DAT-D2R, both co-immunoprecipitation and 
quantitative PLA parameters showed no significant differences between both experimental groups 
(Fig. 4C, D). 
Discussion 
In sum, our results show that prolonged 12x basal GDNF over-expression induces both DA 
uptake decrease and TH down-regulation, while 3x basal GDNF over-expression induces DA uptake 
decrease but not TH down-regulation. The decrease in DA uptake was associated with the formation 
of DAT dimers and changes in DAT- α-synuclein interaction but not in DAT expression levels or its 
compartmental distribution.  
Tyrosine hydroxylase and DAT, which are responsible for the synthesis and uptake of DA 
respectively, are pivotal players in DA signalling. Thus, potential antiparkinsonian therapies should 
preserve TH activity to maintain DA synthesis, but if possible, also regulate DAT activity to maintain 
DA inputs on postsynaptic receptors and to reduce oxidative stress in surviving neurons. The fact that 




Georgievska et al., 2004), suggests that other actors in DA handling, e.g., DAT, may be involved in 
the adaptive response induced by prolonged GDNF transduction. Consistent with this idea, previous 
studies have shown an inverse relationship between GDNF and DAT expressions. For example, DAT 
activity is exacerbated in the striatum of GDNF heterocygous mice (Boger et al., 2007; Littrell et al., 
2012). In addition, data from our group show that constitutive GDNF mRNA levels in the ventral 
striatum are higher than in the dorsal striatum, while DAT protein levels and activity are higher in the 
dorsal striatum than in the ventral striatum (Barroso-Chinea et al., 2005; Afonso-Oramas et al., 
2009). In this respect, Zhu and coworkers (2015) have recently showed that the Rho-family guanine 
nucleotide exchange factor protein Vav2 interacts with the GDNF receptor tyrosine kinase Ret, 
forming a functional complex that downregulates DAT activity. Interestingly, Vav2 is robustly 
expressed in the ventral striatum but not in the dorsal striatum (Zhu et al., 2015), suggesting that the 
Vav2-Ret interaction may be involved in the differential regulation and functional meaning of DAT 
between dorsal and ventral striata.    
By using intrastriatal injection of an AAV-tetON-GDNF vector and DOX treatment in a dose 
range of 0.01-3 mg/ml in drinking water, here we show that chronic GDNF release promotes a 
decrease in DAT activity at an expression level (3x basal levels) lower than that required for TH 
down-regulation (12x basal levels). We have to note that although the catalytic activity of TH was 
not directly quantified, the close relationship between Ser40 phosphorylation and TH activity 
(Dunkley et al., 2004; Daubner et al., 2011; Dickson and Briggs, 2013) allows us to assume that TH 
activity is preserved in AAV-tetON-GDNF- injected rats receiving 0.5 mg/ml DOX.  
A large body of evidence indicates that conventional DAT regulation involves protein 
internalization for it to be thereafter recycled back to the plasma membrane or degraded through the 
autophagy lysosome pathway (Miranda and Sorkin, 2007; Eriksen et al., 2010a). However, the 
decline in DA uptake found here after 0.5 mg/ml (3x GDNF basal levels) or 3 mg/ml DOX (12x 
GDNF basal levels) was not associated with changes in the total expression or compartmental 
distribution of DAT. Noteworthy, the increase in DA uptake in mice with partial GDNF gene 
delection is also not paralleled by changes in DAT expression (Boger et al., 2007). Thus, DA uptake 
may be down- or up-regulated by prolonged GDNF over- or under-expression respectively, without 
affecting the total DAT expression or its subcellular distribution, suggesting the participation of 
alternative mechanisms. An increasing number of protein-protein interactions have showed to be 
involved in DAT trafficking and its recruitment at the plasma membrane (Eriksen et al., 2010b), with 
some of them, i.e. DAT-DAT, DAT-D2R and DAT- α-synuclein, playing a critical role in DAT 
function (Hastrup et al., 2001; Wersinger and Sidhu, 2005; Lee et al., 2007; Oaks and Sidhu, 2013). 




show that the decrease in DA uptake following prolonged GDNF release is paralleled by an increase 
in DAT dimerization and DAT-α-synuclein interaction. In this regard, we have also recently found 
that prolonged treatment with the preferential D3R agonist pramipexole promotes a decrease in DA 
uptake mediated by changes in DAT interactions with its proteome partners (Castro-Hernandez et al., 
2015). Thus, changes in DAT-protein interactions may act as adaptive mechanisms of DA-neurons to 
regulate DA uptake in response to different long-term stimuli. Interestingly, while DAT dimerization 
is enhanced after prolonged exposition to both pramipexole and GDNF, DAT-D2R interaction is 
modified by pramipexole but not by GDNF, and DAT- α-synuclein interaction is strongly modified 
by GDNF but not by pramipexole. Thus, although further studies involving other DAT intereactions 
are needed, the results suggest that some of them, i.e. DAT-DAT, may be sensitive to different 
conditions, while others, i.e. DAT-D2R and DAT-α-synuclein, respond to specific ones.   
Studies in rodents and heterologous expression systems indicate that DAT and other members 
of the sodium symporter family, such as norepinephrine and serotonin transporters, are assembled as 
homodimers in the endoplasmic reticulum, and that dimerization is required for their trafficking to 
the plasma membrane (Kilic and Rudnick, 2000; Hastrup et al., 2001; Torres et al., 2003). In 
addition, different degrees of oligomerization can coexist in a single cell independently of the 
transporter density at the plasma membrane (Anderluch et al., 2014). However, the functional 
meaning of oligomeric forms in the physiology, pathophysiology and pharmacology of transporters 
has not been elucidated. Consistent with previous studies using western-blot under non-reducing 
conditions (Baucum et al., 2004; Hadlock et al., 2009), most striatal DAT in sham-treated rats is 
monomeric (75kDa), with only a small DAT amount showing a molecular weight that corresponds to 
the dimeric form (~150 kDa). The inversion of this immunolabelling pattern, consisting in an 
increase in labelling intensity at 150 kDa and a decrease in that at 75 kDa, observed after prolonged 
GDNF over-expression suggests a strengthening of DAT-DAT interactions. Similar changes in the 
DAT expression pattern were found, together with a DA uptake decline, after prolonged treatment 
with pramipexole (Castro-Hernández et al., 2015) and repeated injections of methamphetamine 
(Baucum et al., 2004), suggesting a role of DAT dimerization in DA uptake regulation. The evidence 
of DAT-DAT PLA signals and the increase of them after GDNF over-expression confirm that the 
150 kDa band corresponds, at least in part, to DAT dimers. Both the number and the average size of 
DAT-DAT PLA dots increased after GDNF treatment. The quantitative analysis of PLA signals is 
currently based on dot count, with the dot number being considered an index of the number of 
protein-protein interactions (Aubele et al., 2010; Aranguren et al., 2013), while the meaning of dot 




of two or more PLA signals localized close to each other or the formation of higher order DAT-DAT 
oligomeric forms. However, until direct evidence provides a solid explanation of this phenomenon 
we must be cautious in its interpretation.  
Alpha-synuclein is a presynaptic protein whose functions have not been entirely clarified. The 
interest in the role of α-synuclein in DA homeostasis comes from the finding of α-synuclein 
accumulation in Lewy bodies in parkinsonian brains (Baba et al., 1998), and mutations in the α-
synuclein gene in familiar forms of PD (Polymeropoulos et al., 1997). Alpha-synuclein has been 
involved in the synthesis, vesicular storage and uptake of DA (Perez et al., 2002; Wersinger and 
Sidhu, 2005). A direct DAT- α-synuclein interaction was identified for the first time by Lee et al. 
(2001), and thereafter confirmed by other authors (Wersinger and Sidhu, 2003). This interaction can 
operate at different stages of DAT maturation, including its release from the endoplasmic reticulum, 
trafficking through cytoskeleton, and recruitment at the plasma membrane (Jeannotte and Sidhu, 
2007; Colla et al., 2012; Oaks et al., 2013). Current data indicate that, in contrast to that occurring in 
α-synuclein over-expression or mutation (Polymeropoulos et al., 1997; Bennett, 2005; Sulzer et al., 
2010), under physiological conditions α-synuclein has a protective effect on DA-neurons. 
Furthermore, this effect is mediated by its interaction with DAT which acts as a negative modulator 
in DAT maturation and trafficking, impeding DAT insertion in the plasma membrane, the uptake of 
DA, and consequently, reducing the oxidative burden in DA-cells (Oaks and Sidhu, 2013). In this 
context, the finding of an increase in DAT-α-synuclein co-immunoprecipitation and PLA signals, 
without changes in total α-synuclein levels, indicates that GDNF promotes this interaction as a long-
term adaptive mechanism, contributing to the DA uptake decrease and probably to its protective 
effect on DA-cells.  
In conclusion, the use of adeno-associated regulatable vectors and exogenous drugs in a dose-
dependent manner allows us to find a point of human GDNF gene transduction at which DAT, but 
not TH, is regulated. The fact that DA uptake is more sensitive to prolonged GDNF delivery than DA 
synthesis indicates that at appropriate GDNF transduction levels, DA uptake, and consequently the 
oxidative burden in DA-cells, may be reduced without interfering with DA synthesis, preventing 
long-term side effects related to transgene over-expression. This fact may be of interest in the 
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Striatal GDNF expression. (A) GDNF protein levels (pg/mg protein) measured by ELISA in rat 
striata 5 weeks after PBS (sham) or viral vector (AAV-tetON-GFP or AAV-tetON-GDNF) injection. 
Viral vector injected rats were treated with different doses of DOX (0.01, 0.03, 0.5 or 3 mg/ml) in the 
drinking water. The striatal GDNF levels in AAV-tetON-GDNF injected rats receiving 0.5 mg/ml 
DOX were 3 times higher than in sham rats and AAV-tetON-GFP-injected rats receiving 0.01 and 3 
mg/ml DOX. In AAV-tetON-GDNF injected rats receiving 3 mg/ml DOX, GDNF levels were 12 
times higher than in sham and AAV-tetON-GFP-injected rats. (B-I) Immunohistochemistry for 
GDNF in the striatum of sham rats (B) and viral vector injected rats treated with 0.5 (F) and 3 mg/ml 
DOX (D, H). (C, E, G and I) High-power magnification microphotographs of B, D, F and H, 
respectively. GDNF staining was not detected in the striatum of sham rats (C) and AAV-tetON-GFP-
injected rats treated with 3mg/ml DOX (E). Sparse GDNF positive cells were detected in the striatum 
of AAV-tetON-GDNF-injected rats treated with 0.5 mg/ml DOX (G). Striatal tissue was intensely 
immunoreactive for GDNF in AAV-tetON-GDNF-injected rats treated with 3 mg/ml DOX (H, I). 
Scale bar in H (for B, D, F and H), 800 μm; in I (for C, E, G and  ), 50 μm.  
Figure 2 
(A) Western-blot for native TH (TH) and TH phsophorylated at serine 40 (THp40) in whole striatal 
extracts. (B) Western-blot for DAT in whole striatal extracts and plasma membranes of striatal 
synaptosomes. (C) Striatal DA uptake. Both TH and THp40 were decreased in the striatum of AAV-
tetON-GDNF injected rats treated with 3 mg/ml DOX. No differences were found in the total and 
membrane DAT levels between sham rats and viral vector injected rats treated with different DOX 
doses. However, the striatal DA uptake was significantly reduced in AAV-tetON-GDNF injected rats 
receiving 0.5 and 3 mg/ml DOX, returning to normal levels after 20 days without DOX.  β-act, β-
actin; synt, syntaxin.  
Figure 3 
Effects of GDNF over-expression on DAT-DAT interaction. (A) Western-blot under non-reducing 
conditions revealed a weak band at 150 kDa, besides that at 75 kDa, in the striatum of sham rats (lane 
1), AAV-tetON-GFP-injected rats treated with 3 mg/ml DOX (lane 2), and AAV-tetON-GDNF-
injected rats treated with 0.03 mg/ml DOX (lane 3). The high weight band was significantly more 
intense in labeling and that at 75 kDa became weaker in AAV-tetON-GDNF-injected rats receiving 
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0.5 and 3 mg/ml DOX (lanes 4 and 5) compared with sham rats (p< 0.01). (B) DAT–DAT in situ 
proximity ligation assay (PLA, left) combined with TH immunofluorescence (center) in the striatum 
of sham rats and viral vectors-injected rats treated with 0.5 mg/ml DOX. The quantitative analysis 
(on the right) showed an increase in both number (top) and size (bottom) of PLA dots in AAV-
tetON-GDNF-injected rats treated with 0.5 mg/ml DOX compared with sham rats and AAV-tetON-
GFP-injected rats treated with 0.5 mg/ml DOX (C and D; p< 0.01). Arrows indicate that DAT–DAT 
PLA signals (red) localize in DA-terminals (green). Quantitative analysis was performed in 5 animals 
per group (see the Material and methods section). In the size diagram, the numbers indicate the 
average size (pixels) of PLA signals. Each dot corresponds to 8 PLA signals in a field of 200 μm2
from a representative animal. β-act, β-actin. Scale bar in B, 5 μm. 
Figure 4. 
GDNF over-expression modifies DAT-α synuclein but not DAT-D2R interaction. (A) 
Immunoprecipitation for DAT (IP-DAT) and immunoblotting for α-synuclein (IB-α Syn) and DAT 
(IB-DAT).  The quantity of co-immunoprecipitated α-synuclein was higher in AAV-tetON-GDNF-
injected DOX (0.5 and 3 mg/ml)-treated rats (lanes 4 and 5) than in sham rats and AAV-tetON-GFP-
injected DOX (3 mg/ml)-treated rats (lanes 2 and 3; p<0.01). Lane 1 (IgG), control 
immunoprecipitation using non-immune IgG. (B) PLA for DAT and α-synuclein in the striatum of 
AAV-tetON-GFP-injected rats (left) and AAV-tetON-GDNF-injected rats (right) treated with 0.5 
mg/ml DOX. The PLA analysis showed that GDNF over-expression increases the number and size of 
PLA dots (p<0.01 vs AAV-tetON-GFP). (C) Immunoprecipitation for D2R (IP-D2R) and 
immunoblotting for DAT (IB-DAT) and D2R (IB-D2R). (D) PLA for DAT and D2R in the striatum. 
No differences were found in the levels of co-immunoprecipitated DAT among sham rats and AAV-
tetON-GFP- and AAV-tetON-GDNF-injected DOX-treated rats, and in the PLA analysis between 
both viral vector-injected DOX-treated rats. In (B and D), n = 5 animals/group, the numbers in the 
size diagram indicate the average size (pixels) of PLA signals. Each dot corresponds to 8 PLA signals 



















Striatal GDNF over-expression is precisely regulated in AAV-tetON-GDNF injected rats. 
12x GDNF over-expression promotes DA uptake decrease and TH down-regulation.  
3x GDNF over-expression promotes DA uptake decrease but not TH down-regulation. 
The DA uptake decrease is associated with changes in DAT protein-protein interactions. 
